Abstract
Mortality in patients with infective endocarditis (IE) remains high. The existing risk scores are relatively complex with limited clinical application. This study was conducted to establish a new risk model to predict in-hospital and 6-month mortality in IE patients. A total of 1549 adult patients with definite IE admitted to Guangdong Provincial People’s Hospital (n=1354) or Xiamen Cardiovascular Hospital (n=195) were included. The derivation cohort consisted of 1141 patients. The score was developed using the multivariate stepwise logistic regression analysis for in-hospital death. Bootstrap analysis was used for validation. Discrimination and calibration were evaluated by the receiver operating characteristic curve and the Hosmer–Lemeshow goodness-of-fit test. Six risk factors were used as score parameters (1 point for each): aortic valve affected, previous valve replacement surgery, severe heart failure, elevated serum direct bilirubin, moderate–severe anemia and acute stage. The predictive value and calibration of the ASSESS-IE score for in-hospital death were excellent in the derivation (area under the curve [AUC]=0.781, p<0.001; Hosmer–Lemeshow p=0.948) and validation (AUC=0.779, p<0.001; Hosmer–Lemeshow p=0.520) cohorts. The score remained excellent in bootstrap validation (AUC=0.783). The discriminatory ability of the ASSESS-IE score for in-hospital (AUC: 0.781 vs. 0.799, p=0.398) and 6-month mortality (AUC: 0.778 vs. 0.814, p=0.040) were similar with that of Park’s score which comprised 14 variables. The ASSESS-IE risk score is a new and robust risk-stratified tool for patients with IE, which might further facilitate clinical decision-making.
Graphical abstract
Similar content being viewed by others
Data Availability
The data will be shared on reasonable request to the corresponding author.
Abbreviations
- IE :
-
Infective endocarditis
- ALT :
-
Alanine aminotransferase
- LVEF :
-
Left ventricular ejection fraction
- PASP :
-
Pulmonary artery systolic pressure
- eGFR :
-
Estimated glomerular filtration rate
- CKD-EPI :
-
Chronic Kidney Disease Epidemiology Collaboration
- NYHA :
-
New York Heart Association
References
Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016;387(10021):882–93. https://doi.org/10.1016/S0140-6736(15)00067-7.
Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015;385(9974):1219–28. https://doi.org/10.1016/S0140-6736(14)62007-9.
Olmos C, Vilacosta I, Fernandez-Perez C, Bernal JL, Ferrera C, Garcia-Arribas D, et al. The evolving nature of infective endocarditis in Spain: a population-based study (2003 to 2014). J Am Coll Cardiol. 2017;70(22):2795–804. https://doi.org/10.1016/j.jacc.2017.10.005.
Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. 2017;317(16):1652–60. https://doi.org/10.1001/jama.2017.4287.
Shah ASV, McAllister DA, Gallacher P, Astengo F, Rodriguez Perez JA, Hall J, et al. Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis. Circulation. 2020;141(25):2067–77. https://doi.org/10.1161/CIRCULATIONAHA.119.044913.
Iung B, Duval X. Infective endocarditis: innovations in the management of an old disease. Nat Rev Cardiol. 2019;16(10):623–35. https://doi.org/10.1038/s41569-019-0215-0.
Kumar A, Anstey C, Tesar P, Shekar K. Risk factors for mortality in patients undergoing cardiothoracic surgery for infective endocarditis. Ann Thorac Surg. 2019;108(4):1101–6. https://doi.org/10.1016/j.athoracsur.2019.05.029.
Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222–32. https://doi.org/10.1093/eurheartj/ehz620.
Ren Z, Mo X, Chen H, Peng J. A changing profile of infective endocarditis at a tertiary hospital in China: a retrospective study from 2001 to 2018. BMC Infect Dis. 2019;19(1):945. https://doi.org/10.1186/s12879-019-4609-8.
De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. Sci World J. 2012;2012:307571. https://doi.org/10.1100/2012/307571.
Gaca JG, Sheng S, Daneshmand MA, O'Brien S, Rankin JS, Brennan JM, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg. 2011;141(1):98–106. https://doi.org/10.1016/j.jtcvs.2010.09.016.
Chee QZ, Tan YQ, Ngiam JN, Win MT, Shen X, Choo JN, et al. The SHARPEN clinical risk score predicts mortality in patients with infective endocarditis: an 11-year study. Int J Cardiol. 2015;191:273–6. https://doi.org/10.1016/j.ijcard.2015.04.236.
Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E, et al. Validated risk score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc. 2016;5(4):e003016. https://doi.org/10.1161/JAHA.115.003016.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128. https://doi.org/10.1093/eurheartj/ehv319.
Varela L, Lopez-Menendez J, Redondo A, Fajardo ER, Miguelena J, Centella T, et al. Mortality risk prediction in infective endocarditis surgery: reliability analysis of specific scores. Eur J Cardiothorac Surg. 2018;53(5):1049–54. https://doi.org/10.1093/ejcts/ezx428.
Rizzo V, Salmasi MY, Sabetai M, Primus C, Sandoe J, Lewis M, Woldman S, Athanasiou T. Infective endocarditis: do we have an effective risk score model? A systematic review. Front Cardiovasc Med. 2023;10:1093363. https://doi.org/10.3389/fcvm.2023.1093363.
Hurrell H, Roberts-Thomson R, Prendergast BD. Non-infective endocarditis. Heart. 2020;106(13):1023–9. https://doi.org/10.1136/heartjnl-2019-315204.
Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–8. https://doi.org/10.1086/313753.
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713. https://doi.org/10.1016/j.echo.2010.05.010.
Garcia-Granja PE, Lopez J, Vilacosta I, Sarria C, Dominguez F, Ladron R, et al. Predictive model of in-hospital mortality in left-sided infective endocarditis. Rev Esp Cardiol (Engl Ed). 2020;73(11):902–9. https://doi.org/10.1016/j.rec.2019.11.003.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.
Chu VH, Park LP, Athan E, Delahaye F, Freiberger T, Lamas C, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Circulation. 2015;131(2):131–40. https://doi.org/10.1161/CIRCULATIONAHA.114.012461.
Costa MA, Wollmann DR Jr, Campos AC, Cunha CL, Carvalho RG, Andrade DF, et al. Risk index for death by infective endocarditis: a multivariate logistic model. Rev Bras Cir Cardiovasc. 2007;22(2):192–200. https://doi.org/10.1590/s0102-76382007000200007.
Martinez-Selles M, Munoz P, Arnaiz A, Moreno M, Galvez J, Rodriguez-Roda J, et al. Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. Int J Cardiol. 2014;175(1):133–7. https://doi.org/10.1016/j.ijcard.2014.04.266.
Di Mauro M, Dato GMA, Barili F, Gelsomino S, Sante P, Corte AD, et al. A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE. Int J Cardiol. 2017;241:97–102. https://doi.org/10.1016/j.ijcard.2017.03.148.
Olmos C, Vilacosta I, Habib G, Maroto L, Fernandez C, Lopez J, et al. Risk score for cardiac surgery in active left-sided infective endocarditis. Heart. 2017;103(18):1435–42. https://doi.org/10.1136/heartjnl-2016-311093.
Gatti G, Perrotti A, Obadia JF, Duval X, Iung B, Alla F, et al. Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis. J Am Heart Assoc. 2017;6(7) https://doi.org/10.1161/JAHA.116.004806.
Gatti G, Benussi B, Gripshi F, Della Mattia A, Proclemer A, Cannata A, et al. A risk factor analysis for in-hospital mortality after surgery for infective endocarditis and a proposal of a new predictive scoring system. Infection. 2017;45(4):413–23. https://doi.org/10.1007/s15010-016-0977-9.
Varela Barca L, Fernandez-Felix BM, Navas Elorza E, Mestres CA, Munoz P, Cuerpo-Caballero G, et al. Prognostic assessment of valvular surgery in active infective endocarditis: multicentric nationwide validation of a new score developed from a meta-analysis. Eur J Cardiothorac Surg. 2020;57(4):724–31. https://doi.org/10.1093/ejcts/ezz328.
Gatti G, Sponga S, Peghin M, Givone F, Ferrara V, Benussi B, et al. Risk scores and surgery for infective endocarditis: in search of a good predictive score. Scand Cardiovasc J. 2019;53(3):117–24. https://doi.org/10.1080/14017431.2019.1610188.
Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. JAMA. 2018;320(1):72–83. https://doi.org/10.1001/jama.2018.7596.
El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Relationship between heart disease and liver disease: a two-way street. Cells. 2020;9(3). https://doi.org/10.3390/cells9030567.
Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions. JACC Heart Fail. 2019;7(2):87–97. https://doi.org/10.1016/j.jchf.2018.10.007.
Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis. 2013;17(2):301–17. https://doi.org/10.1016/j.cld.2012.11.001.
Cuervo G, Escrihuela-Vidal F, Gudiol C, Carratala J. Current challenges in the management of infective endocarditis. Front Med (Lausanne). 2021;8:641243. https://doi.org/10.3389/fmed.2021.641243.
Wei XB, Wang Y, Liu YH, Huang JL, Yu DQ, Chen JY. Effect of conjugated bilirubin on clinical outcomes in infective endocarditis. Eur J Clin Microbiol Infect Dis. 2019;38(12):2259–66. https://doi.org/10.1007/s10096-019-03670-4.
Funding
This study was supported by grants from the National Natural Science Foundation of China (Grant No. 82002014), Natural Science Foundation of Guangdong Province (grant no. 2021A1515010107), Project of Administration of Traditional Chinese Medicine of Guangdong Province of China (Grant No. 20221003), Science and Technology Projects of Guangzhou (Grant No. 201903010097), and Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention (Grant No. Y0120220151). The funders had no role in the study design, data collection and analysis, decision to publish, nor preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
JC, DY, and SW were involved in the conception and design of this study. XW, PR, YN, BF, TY, XJ, HG, YX, YL, ZW, and JY contributed to data collection and data interpretation. XW, PR, and YN constructed the manuscript, which was revised and approved by all the authors for publication.
Corresponding authors
Ethics declarations
Ethical Approval
This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Guangdong Provincial People’s Hospital (NO. GDREC2020098)
Conflict of Interest
The authors declare no competing interests.
Additional information
Associate Editor Rupak Mukherjee oversaw the review of this article
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Xuebiao Wei, Peng Ran and, Yuxin Nong are considered as co-first authors.
Supplementary Information
ESM 1
(DOCX 4141 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wei, X., Ran, P., Nong, Y. et al. ASSESS-IE: a Novel Risk Score for Patients with Infective Endocarditis. J. of Cardiovasc. Trans. Res. (2023). https://doi.org/10.1007/s12265-023-10456-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12265-023-10456-9